Drug Trial Radar · NCT00579956
A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis
Last checked: Nov 19, 2026Latest source record: Jun 4, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
750
Planned (sponsor's estimate)
Start
Dec 2007
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mahidol University; Wellcome Trust
- First posted
- Dec 24, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Melioidosis, an infection caused by the bacterium Burkholderia pseudomallei, is a major cause of community-acquired septicaemia in northeast Thailand. Common manifestations include cavitating pneumonia, hepatic and splenic abscesses, and soft tissue and joint infections. Despite improvements in diagnostic procedures and treatment, the mortality of severe melioidosis remains unacceptably high - approximately 35% with currently used antibiotics (ceftazidime or co-amoxiclav). There is clear evidence that antibiotics can affect mortality; the use of ceftazidime rather than previous regimens (doxycycline + chloramphenicol + co-trimoxazole) led to a 50% reduction in mortality from 80% to 35%. However, the mortality in the first 48 hours has not been altered by any treatment regimen. A key question is whether alternative antibiotics could improve early outcome. The hypothesis tested is that meropenem is superior to ceftazidime in terms of mortality for the treatment of melioidosis.
Conditions
- Melioidosis
Interventions
MeropenemDrug
Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
CeftazidimeDrug
Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
Primary outcomes
What the sponsor says the trial is designed to measure.
- All cause mortalityTime frame: In hospital
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Udon Thani General Hospital
Udon Thani, Thailand · Recruiting
Sappasithiprasong Hospital
Ubonratchathani, Changwat Ubon Ratchathani, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.